Regulation of cardiac fibroblast extracellular matrix production by bradykinin and nitric oxide

被引:112
作者
Kim, NN
Villegas, S
Summerour, SR
Villarreal, FJ
机构
[1] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA
[2] Univ Calif San Diego, Dept Bioengn, San Diego, CA 92103 USA
关键词
bradykinin; nitric oxide; collagen; fibronectin; cardiac fibrosis; cardiac remodeling; angiotensin-converting enzyme inhibitors;
D O I
10.1006/jmcc.1998.0887
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The beneficial effects of angiotensin-converting enzyme inhibitors on ameliorating cardiac fibrosis have been partially attributed to their ability to prevent the degradation of kinins, The potential role of bradykinin and the related signaling molecule nitric oxide (NO) in modulating extracellular matrix (ECM) production was examined in primary cultures of adult rat cardiac fibroblasts, Treatment of fibroblasts with 5 nhl bradykinin for 24 h led to a reduction in steady-state mRNA levels for fibronectin (34 +/- 7%) and collagens type I (19 +/- 8%) and type III (48 +/- 4%), as determined by Northern blot analysis. The NO synthase inhibitor L-NAME attenuated the reduction observed in fibronectin and collagen mRNA levels in response to bradykinin. The NO donor DETA NONOate (100 mu M) mimicked the effects of bradykinin on ECM mRNA levels, Protein levels of soluble fibronectin, assessed in conditioned medium by ELISA, were decreased by 14 +/- 4%, and 21 +/- 4% after 48 h treatment with 1 mu M bradykinin and 100 mu M DETA NONOate, respectively. Bradykinin stimulated intracellular cGMP accumulation 73.7 +/- 10.3% after 10 min of treatment, Cell proliferation rates at 48 h were unaffected by bradykinin, but were reduced by 26 +/- 12% by 100 mu M DETA NONOate. These data indicate that bradykinin downregulates ECM protein production in cardiac fibroblasts and suggest that NO and the related signaling molecule cGMP may play an important role in mediating this reponse. (C) 1999 Academic Press.
引用
收藏
页码:457 / 466
页数:10
相关论文
共 50 条
[1]  
BAUM BJ, 1978, J BIOL CHEM, V253, P3391
[2]  
BAUM BJ, 1980, J BIOL CHEM, V255, P2843
[3]   RAMIPRILAT INCREASES BRADYKININ OUTFLOW FROM ISOLATED HEARTS OF RAT [J].
BAUMGARTEN, CR ;
LINZ, WG ;
KUNKEL, G ;
SCHOLKENS, BA ;
WIEMER, G .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 108 (02) :293-295
[4]   SIMULTANEOUS MEASUREMENTS OF CA2+ AND NITRIC-OXIDE IN BRADYKININ-STIMULATED VASCULAR ENDOTHELIAL-CELLS [J].
BLATTER, LA ;
TAHA, Z ;
MESAROS, S ;
SHACKLOCK, PS ;
WIER, WG ;
MALINSKI, T .
CIRCULATION RESEARCH, 1995, 76 (05) :922-924
[5]   ATTENUATION OF LEFT-VENTRICULAR DILATATION AFTER ACUTE MYOCARDIAL-INFARCTION BY EARLY INITIATION OF ENALAPRIL THERAPY [J].
BONARJEE, VVS ;
CARSTENSEN, S ;
CAIDAHL, K ;
NILSEN, DWT ;
EDNER, M ;
BERNING, J .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 72 (14) :1004-1009
[6]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[7]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[8]  
CONKLIN BR, 1988, J PHARMACOL EXP THER, V244, P646
[9]   [HYP3]-BRADYKININ AND [HYP3]-LYS-BRADYKININ INTERACT WITH B2-BRADYKININ RECEPTORS AND STIMULATE INOSITOL PHOSPHATE PRODUCTION IN CULTURED HUMAN FIBROBLASTS [J].
DENGLER, R ;
FAUSSNER, A ;
MULLERESTERL, W ;
ROSCHER, AA .
FEBS LETTERS, 1990, 262 (01) :111-114
[10]  
DUBEY RK, 1994, J PHARMACOL EXP THER, V269, P402